Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Revenue Growth Recovery in ProgressRecovering
Percentile Rank33
Studio
Year-over-Year Change

Year-over-year revenue growth rate

Percentile
P33
Within normal range
vs 3Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
PeriodValue
Q4 2025-1.95%
Q3 2025-5.93%
Q2 20258.96%
Q1 202523.31%
Q4 202424.23%
Q3 2024-14.25%
Q2 202433.86%
Q1 2024-41.98%
Q4 202333.65%
Q3 2023-25.42%
Q2 202340.92%
Q1 2023-27.50%
Q4 202213.27%
Q3 2022-61.45%
Q2 2022104.81%
Q1 20226.97%
Q4 202118.30%
Q3 2021-7.86%
Q2 20211.16%
Q1 2021-7.75%
Q4 2020-5.48%
Q3 2020-33.45%
Q2 20201.88%
Q1 202027.21%
Q4 2019-24.38%
Q3 2019-8.76%
Q2 201938.72%
Q1 201921.41%
Q4 201812.57%
Q3 20188.97%
Q2 20186.23%
Q1 2018-47.40%
Q4 2017111.51%
Q3 201744.75%
Q2 201736.69%
Q1 20171259.28%
Q4 20160.00%
Q3 20160.00%
Q2 20160.00%
Q1 20160.00%